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Abstract
Background: DNA microarray profiling performed on clinical tissue specimens can potentially provide
significant information regarding human cancer biology. Biopsy cores, the typical source of human tumor
tissue, however, generally provide very small amounts of RNA (0.3–15 µg). RNA amplification is a
common method used to increase the amount of material available for hybridization experiments. Using
human xenograft tissue, we sought to address the following three questions: 1) is amplified RNA
representative of the original RNA profile? 2) what is the minimum amount of total RNA required to
perform a representative amplification? 3) are the direct and indirect methods of labeling the hybridization
probe equivalent?
Methods: Total RNA was extracted from human xenograft tissue and amplified using a linear amplification
process. RNA was labeled and hybridized, and the resulting images yielded data that was extracted into
two categories using the mAdb system: "all genes" and "outliers". Scatter plots were generated for each
slide and Pearson Coefficients of correlation were obtained.
Results: Results show that the amplification of 5 µg of total RNA yields a Pearson Correlation Coefficient
of 0.752 (N = 6,987 genes) between the amplified and total RNA samples. We subsequently determined
that amplification of 0.5 µg of total RNA generated a similar Pearson Correlation Coefficient as compared
to the corresponding original RNA sample. Similarly, sixty-nine percent of total RNA outliers were
detected with 5 µg of amplified starting RNA, and 55% of outliers were detected with 0.5 µg of starting
RNA. However, amplification of 0.05 µg of starting RNA resulted in a loss of fidelity (Pearson Coefficient
0.669 between amplified and original samples, 44% outlier concordance). In these studies the direct or
indirect methods of probe labeling yielded similar results. Finally, we examined whether RNA obtained
from needle core biopsies of human tumor xenografts, amplified and indirectly labeled, would generate
representative array profiles compared to larger excisional biopsy material. In this analysis correlation
coefficients were obtained ranging from 0.750–0.834 between U251 biopsy cores and excised tumors, and
0.812–0.846 between DU145 biopsy cores and excised tumors.
Conclusion: These data suggest that needle core biopsies can be used as reliable tissue samples for tumor
microarray analysis after linear amplification and either indirect or direct labeling of the starting RNA.
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Background
Recent studies suggest that DNA microarray profiling per-
formed on clinical specimens may provide information
directly applicable to cancer diagnosis and treatment. One
application of microarray analysis is aimed at differentiat-
ing subgroups of cancers using gene expression profiling,
also referred to as class discovery [1-4]. Golub et al. used
gene expression profiling of patient leukemia cells to dis-
tinguish acute myeloid leukemia (AML) from acute lym-
phoblastic leukemia (ALL) [1]. Moreover, they showed
that subsets of leukemia cells that morphologically
appeared to be ALL had a gene expression profile and
response to therapy that was more consistent with AML,
thus a new class of leukemia was described. Microarray
analysis was also used to identify a subset of ALL tumors
with a distinct gene expression profile that respond poorly
to standard therapy [4]. Subgroup profiles have also been
developed for other histologically homogeneous tumors
such as diffuse B-cell lymphomas and hereditary breast
cancers [2,3]. A diffuse large B-cell lymphoma (DLBCL)
tumor cohort was divided into subsets of tumors with dis-
tinct gene expression profiles that correlated with overall
survival [2]. Hedenfalk et al. compared gene expression
profiles of breast tumors from women with and without
BRCA1 or BRCA2 mutations. They showed that these two
classes of breast tumors displayed different gene expres-
sion profiles and created a BRCA1/BRCA2 subclass. Such
studies aimed at delineating the gene expression profiles
of subtypes of tumors that exist within a purportedly
homogeneous tumor population may not only aid in can-
cer diagnosis, but may also provide novel insight into the
genetic mechanisms of oncogenesis.
In addition to cancer diagnosis, gene profiling is being
explored as a means of predicting tumor treatment
response, a long sought after goal of clinical oncology.
Towards this end, a number of studies have related tumor
gene expression profiles to treatment outcome and
response to a given cytotoxic therapy, a process termed
class prediction. Tumor gene expression profiles were gen-
erated for a series of patients with esophageal cancer
treated with surgery and adjuvant chemotherapy resulting
in the identification of an expression profile that corre-
lated with longer survival and possibly tumor chemosen-
sitivity [5]. Similarly, clinical outcomes and gene
expression profiles were compared in subsets of patients
with longer survival in B-cell lymphomas, AML and breast
cancer, which produced gene expression profile that cor-
related with tumor response in each of these tumor types
[6-8].
Thus, initial reports have suggested that incorporating
gene expression profiling into clinical trials may provide
novel information relevant to both cancer diagnosis and
treatment. However, to fully investigate the potential clin-
ical applicability/value of microarray analysis will necessi-
tate the performance of large prospective clinical trials.
Such trials will confront a number of confounding varia-
bles including the uniform collection and preparation of
RNA [9], the stability of the reference and experimental
samples over a prolonged period [10] and microarray
quality control over time [11]. However, the most signifi-
cant impediment to performing these studies is likely to
be the small size of the tumor biopsy. In a recent study of
fifty-five breast biopsies obtained using a 14-gauge nee-
dle, the median recovery was only 1.34 µg of RNA (range
100 ng–12.6 µg) [12]. Moreover, Assersohn et al. in their
analysis of breast fine needle aspirates reported a mean
recovery of 202,500 cells, which would correspond to
approximately 100 ng of RNA [13]. Because obtaining
multiple biopsies from the same patient will likely be the
exception, in most clinical trials the majority of gene
expression profiles will have to be generated from single
core biopsies that are likely to yield these small amounts
of starting RNA material. Thus, in an attempt to optimize
and validate procedures for tumor sample sizes relevant to
the clinical setting, we have performed a series of microar-
ray based gene expression analyses on core biopsies from
human tumor xenograft models. These studies included
the evaluation of the representative nature of amplified
RNA compared with the original RNA sample, a compari-
son of direct and in-direct methods of probe labeling and
the determination of the minimum starting RNA material
needed to perform a valid and representative
amplification.
Methods
Tumor xenografts
Three human tumor cell lines were used in this study:
U251, a glioblastoma cell line, and two prostate carci-
noma cell lines DU145 and LNCAP. Each was obtained
from ATCC (Gaithersburg, MD). Xenografts were main-
tained in SCID mice (Jackson Labs, NH) with U251 and
DU145 implanted subcutaneously (sc) and LNCAP con-
sisting of an orthotopic tumor in the prostate gland. Ani-
mals were sacrificed and their tumors, average 350 mm3 in
size, were immediately biopsied with a 14-gauge (2.1 mm
diameter) semi-automatic core biopsy needle (MRI
Devices Corp., Germany). Several biopsies were obtained
in non-necrotic areas of the tumor. Core biopsies were
snap frozen in liquid nitrogen or preserved in RNAlater
(Qiagen.)
RNA amplification
Total RNA was isolated using TRIzol® reagent (Invitrogen)
and purified with RNeasy® mini kits (Qiagen) according to
the manufacturer's instructions. RNA samples and Univer-
sal Human Reference RNA (Stratagene) were amplified
one or two rounds using RiboAmp® RNA Amplification
Kits (Arcturus) per manufacturer's instructions. StartingBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/20
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RNA quantity varied by experiment, between 0.8 and 10
µg of whole tumor samples. The reference RNA for these
experiments was amplified using 10 µg aliquots of Uni-
versal Reference. All amplified samples were purified with
an RNeasy® Kit according to the manufacturer's instruc-
tions and samples assessed for purity by agarose gel elec-
trophoresis, and spectrophotometry was used to
determine concentration.
Probe preparation
For direct labeling ten micrograms of amplified universal
human reference were labeled with cyanine 5-dUTP (Cy5)
and 5 µg of amplified U251 RNA samples were labeled
with cyanine 3-dUTP (Cy3) using SUPER-SCRIPT II and
Oligo (dT) 12–18 (Invitrogen). The method described by
Khan et al., was followed [14]. Labeled probes were puri-
fied using Micro Bio-Spin 6 Chromatography Columns
(Bio-Rad Laboratories) and purified using Microcon-30
spin columns (Millipore, three 400 µl TE washes used).
The final elution was taken up to 17 µl with TRIS EDTA.
For indirect labeling of total RNA, 20 µg of both sample
and reference were diluted into a total of 12 µl of DEPC
water. For amplified RNA, starting material was reduced
to 3 µg of both sample and reference, also diluted into a
total of 12 µl of DEPC water per sample. For total RNA, 1
µl of 500 ng/µl oligonucleotide d(T)12–18 (Stratagene
Fairplay Kit) was added to each tube for cDNA priming.
Amplified samples had 1 µl of 3 µg/µl random primer
(Invitrogen) added to each reaction tube. Samples were
incubated at 70°C for 10 minutes, and cooled on ice. Each
sample then had the following components added: 2 µl of
10 × StrataScript reaction buffer (Stratagene Fairplay Kit),
1 µl of 20 × dNTP mix, 1.5 µl of 0.1 M DTT, and 0.5 µl
Rnase Block. Subsequent to mixing, 1 µl of 50 U/µl
StrataScript RT was added to each tube and tubes were
incubated at 48°C for 25 minutes. Another aliquot of 1 µl
StrataScript RT was added to each tube, and tubes were
incubated for an additional 35 minutes. The resulting
cDNA was purified using a MINElute Kit (Qiagen). Sam-
ples were next coupled to either 111 µg of monofunc-
tional dye for total RNA-derived cDNA, or 55 µg of
monofunctional dye for amplified RNA-derived cDNA.
Reference RNA was always labeled with Cy5; tumor sam-
ples were labeled with Cy3.
Microarray hybridization
Microarray Slides were obtained from the Radiation
Oncology Sciences Program Microarray Lab at the
National Institutes of Health [15]. Slides were 8 k human
slides printed on site using a Named Genes clone set from
Research Genetics (Huntsville, AL), spotted onto poly-L-
lysine coated slides using an OmniGrid arrayer (GeneMa-
chines, San Carlos, CA). Slides were pre-hybridized for at
least one hour at 42°C with 40 µl of pre-hybridization
solution consisting of 5 × SSC, 0.1% SDS, and 1% BSA.
Solution was loaded under M Series Lifterslips (Erie Scien-
tific). Pre-hybridization solution was washed off by rap-
idly plunging the slides in distilled water for 2 minutes,
followed by 100% isopropanol for 2 minutes. Slides were
allowed to air dry prior to sample hybridization. Cy3 and
Cy5 labeled targets were combined together for hybridiza-
tion after dye-coupled cDNA purification. 1 µl of human
COT-1 DNA (Invitrogen) and 1 µl of pd(A)40–60 (Amer-
sham Biosciences) was added to each tube. Targets were
denatured at 100°C for 1 minute before snap cooling on
ice. 20 µl of pre-warmed (42°C) 2 × F-Hybridization
Buffer (50% formamide, 10 × SSC, 0.2% SDS) was added
to each sample. The combined target/hybridization solu-
tion mixture was incubated at 42°C for one minute,
mixed and loaded onto microarray slides. Humidity was
maintained in each chamber through the addition of 20
µl of DEPC water. Slides were hybridized at 42°C over-
night. Post-hybridization washing included: 5 minutes in
2 × SSC + 0.1% SDS, 5 minutes in 1 × SSC, 5 minutes in
0.2 × SSC, and finally 1 minute in 0.05 × SSC. Slides were
dried in a centrifuge set for 25°C at 650 rpm for 3 min-
utes. Slides were scanned at 10 microns using a Genepix®
4000 scanner (Axon Instruments), and images and data
were stored in a database (mAdb) maintained by the
Center for Information Technology, National Institutes of
Health.
Data analysis
Data was extracted into two categories using the mAdb
system: "all genes" and "outliers". "All genes" were
extracted excluding spots flagged as Bad/Not found, and
spots with target diameters less than 50 µm or greater than
300 µm. "Outliers" were defined as spots with a signal to
background ratio ≥2, and an overall signal ≥1,000, genes
required values in 100% of arrays, and the expression
ratio was ≥2 or ≤0.5. Spots were included if either channel
was ≥2,500 but the other criteria were unmet. Target pixels
were 1 SD above the background ≥80%. After extraction,
scatter plots were generated for each slide and Pearson
Coefficients of correlation were obtained.
Results
Amplified versus total RNA
Expanding clinical applications of cDNA microarrays
necessitate the ability to perform arrays with relatively
minute starting amounts of RNA. The most commonly
used method to increase the amount of RNA from a clini-
cal specimen to a level suitable for analysis is through
RNA amplification [16]. However, whether the gene
expression profile generated from amplified RNA is repre-
sentative of that obtained from total RNA has been the
subject of some controversy [17]. To address this issue in
our system, two replicates of amplified RNA and un-
amplified RNA, derived from sc U251 tumors, wereBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/20
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hybridized against amplified reference and un-amplified
reference RNA, respectively. Scatter plots comparing the
total gene expression level of the 2 amplified samples to
each other and the 2 original RNA samples to each other
(figures 1a and 1b) resulted in high correlation coeffi-
cients indicative of the reproducibility of the microarray
platform used in these studies. Earlier publications have
determined that a threshold of 0.70 for the concordance
value is a marker of reproducibility [13,16]. Higher corre-
lations within groups were obtained when just the outliers
were compared (Figures 1d and 1e), consistent with prior
studies [16]. Comparison of the original RNA samples to
the amplified samples from in vivo biopsy cores yielded
similar correlation coefficients, and once again, the outlier
genes have a higher coefficient than the all gene group
(figure 1c and 1f). The outlier genes obtained for the orig-
inal RNA and amplified RNA samples were also com-
pared. Replicates for each group were averaged and the
number of outliers in each determined (data not shown).
In the original RNA sample 263 outliers were detected,
67% of those were also detected within the amplified RNA
sample. Therefore, the amplification of the RNA material
from a U251 tumor biopsy core maintained the majority
of outlier genes found in the un-amplified sample.
RNA detection limits
Although a high concordance existed between our ampli-
fied and non-amplified specimens, the amount of starting
Correlations using amplified and total RNA isolated from U251 tumor Figure 1
Correlations using amplified and total RNA isolated from U251 tumor. (A) Correlations between gene expression 
ratios for all genes using amplified RNA replicates 0.951 (n = 6,841 genes) and (B) total RNA replicates 0.919 (n = 6,981 genes). 
(D) and (E) represent scatter plots and correlations obtained for amplified 0.995 (n = 456 genes) and total replicates 0.995 (n 
= 274 genes), respectively, for outlier gene expression. (C) and (F) Representative correlation between total and amplified 
RNA from one sample 0.73 for all genes (n = 6,987 genes) and 0.945 for outliers (n = 203 genes). Extraction methods for all 
genes and outliers are found in the methods.
Amplified RNA Replicates, All Genes
r = 0.951
ratio, amplified replicate 1
A. B.Total RNA Replicates, All Genes
r = 0.919
C. Total v. Amplified RNA, All Genes
r = 0.73
D.
Amplified RNA Replicates, Outliers
r = 0.995
E. Total RNA Replicates, Outliers
r = 0.995
F. Total v. Amplified RNA, Outliers
r = 0.945BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/20
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RNA material for these experiments was greater than what
might be expected from a core biopsy from a patient's
tumor. We amplified 5 µg of RNA, whereas typical biopsy
core specimens obtained in our clinic using a 14-gauge
needle yield 0.3–3 µg of RNA (unpublished data). To
determine the amount of RNA starting material needed to
amplify and maintain a high concordance with the origi-
nal biopsy specimen, serial dilutions (5 µg, 0.5 µg, and
0.05 µg) of LnCaP tumor biopsy material was used for
amplification. Orthotopic LnCaP tumors were used in this
study to validate that the high correlation seen in the ear-
lier experiments were not specific to sc xenograft tumors.
To control for the potential influence of varying the refer-
ence to sample RNA ratio, reference RNA was correspond-
ingly serially diluted to 5 µg, 0.5 µg and 0.05 µg of starting
material. All samples were then amplified 2 rounds to
generate enough material for hybridization. The compar-
ison of 5 µg of un-amplified RNA versus amplified RNA of
this orthotopic tumor model showed similar coefficients
to the ones derived from the sc U251 model suggesting
that the site of tumor growth does not influence the con-
cordance values (figure 2a). However, the resulting Pear-
son Coefficients indicate a decreasing similarity to the
original specimen as the starting amounts of material are
reduced (figure 2a/2b/2c). We also examined outlier con-
cordance by determining the percentage of original RNA
outliers detected in the 5 µg, 0.5 µg, and 0.05µg of ampli-
fied samples. Three hundred and fifty three genes were
RNA detection limits Figure 2
RNA detection limits. (A) Total RNA versus 5 µg amplified RNA yielded a coefficient of 0.789 after two rounds of amplifi-
cation (n = 6,096 genes) (B) The correlation for all genes between total RNA and a serially diluted 0.5 µg aliquot that was 
removed from the 5 µg sample and amplified 2 rounds yielded a coefficient of 0.7 (n = 6,102 genes). (C) The correlation 
between gene expression ratios for all genes between total RNA and a 0.05 µg aliquot that has been serially diluted from the 
0.5 µg aliquot yielded a coefficient of 0.669 (n = 6,114 genes). (D-F) Venn diagrams depicting outlier concordance between the 
samples featured in (A-C, respectively). Extraction methods for all genes and outliers are found in the methods.
A.
Total RNA v. 5 ug Amplified RNA
r = 0.789
Total RNA v. 0.5 ug Amplified RNA B.
r = 0.70
C.
Total RNA v. 0.05 ug Amplified RNA
r = 0.669
303 
genes
244 genes
109 genes
363 
genes
194 
genes
159 genes 198 genes
145 
genes
155 
genes
D.
Total RNA Outliers (Black)
5 ug Amplified RNA Outliers
Total RNA Outliers (Black)
0.5 ug Amplified RNA Outliers
E. F.
Total RNA Outliers (Black)
0.05 ug Amplified RNA Outliers
(Light Grey) (Light Grey) (Light Grey)BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/20
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identified as outliers for 5 µg of un-amplified RNA, while,
547, 557 and 300 genes were outliers in the 5 µg, 0.5 µg,
and 0.05 µg amplified specimens, respectively (figure 2d/
2e/2f). The overlap in outliers between the 5 µg of original
RNA and each amplified specimen was 244 (69%), 194
(55%), 155 (44%) genes. Although there was concord-
ance between the 5 µg amplified and the original speci-
mens for outlier identification, a 44% concordance for the
outliers in the amplified 0.05 µg sample compared to the
5 µg original sample is below the 0.70 concordance value
sited in the literature as a marker of reproducibility [13].
Direct versus indirect labeling methods
An additional parameter that can determine the amount
of starting RNA material needed is the method of fluoro-
phore labeling. The two methods used to fluorescently
label cDNA probes are direct labeling and indirect
(amino-allyl) labeling. As the indirect method require less
starting material and less expensive labeling dye, it was
important to determine whether the data generated from
these labeling methods was interchangeable. Two repli-
cates of amplified RNA from the U251 sc tumor sample
and reference RNA were labeled via each method, micro-
array analysis performed and scatter plots generated. Pear-
son Coefficients were generated to determine similarity.
For direct labeling, 5 µg of experimental sample and 10 µg
of reference was used and for the indirect method 3 µg of
both the experimental sample and reference was used. The
reproducibility of the hybridization results for both the
direct or indirect method of probe preparation using this
microarray platform was indistinguishable for the all gene
groups (figure 3a/3b). Similarly, the outlier coefficients
from each labeling method were extracted and the directly
labeled replicates yielded a Pearson Coefficient of 0.992
for outliers (n = 647), and indirectly labeled replicates
yielded a Pearson Coefficient of 0.99 for outliers (n = 588)
(data not shown). When directly comparing the method
of probe preparation (figure 3, representative image), a
high correlation was observed in the hybridization results.
Therefore, while using less amplified RNA starting
material, the indirect method of probe preparation yields
similar results to directly labeled samples.
Tumor needle core biopsies versus excised tumor
After determining the limits of RNA amplification and the
optimal method of probe labeling we simulated a patient
biopsy procedure. Three core specimens were taken from
a xenograft tumor, representing the patient biopsies, and
the remainder of the tumor was harvested to represent the
entire gene expression profile. Samples were obtained
from two tumor types, DU145 and U251, both grown in
the flank of SCID mice. The DU145 samples were flash
frozen in liquid nitrogen, whereas the U251 samples were
stored in RNAlater. As the use of liquid nitrogen can be
cumbersome in the operating room, the reagent RNAlater
has been used to preserve RNA specimens at room
Scatter plot images and corresponding Pearson Coefficients between direct and indirect labeling methods Figure 3
Scatter plot images and corresponding Pearson Coefficients between direct and indirect labeling methods. (A) 
Scatter plot of direct labeling replicates yielding a Pearson Coefficient of 0.948 for all genes (n = 7,476 genes). (B) Scatter plot 
of indirect labeling replicates yielding a Pearson Coefficient of 0.924 for all genes (n = 7,474). (C) A representative image of a 
comparison of the gene expression ratios between a direct and indirectly labeled slide. The average Pearson Coefficient gener-
ated comparing labeling methods was 0.895 for all genes (range 0.883–0.911, n = 7,474 genes). Extraction method for all genes 
is found in the methods.
r = 0.948
Direct Replicates, All Genes
A. B.
Indirect Replicates, All Genes
r = 0.924
C.
r = 0.9
Direct v. Indirect, All GenesBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/20
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temperature for up to 24 hours. Therefore, we included
specimens stored in RNAlater to determine whether the
specimens maintained fidelity. All core samples, range of
original RNA 0.8 µg to 5 µg, were amplified and 3 µg of
amplified RNA was indirectly labeled and hybridized
against amplified human reference. Individual cores
served as biologic replicates; 2 excisional tumor biopsies
were obtained and each was analyzed in duplicate.
Comparison of the DU145 excisional biopsy cores gener-
ated average coefficients of 0.90 for all genes (n = 6,711
genes), and 0.99 for outliers (n = 363 genes)(data not
shown). Similarly, U251 excisional biopsies yielded an
average coefficient of 0.90 for all genes (n = 7,078 genes)
and 0.98 for outliers (n = 494 genes). The similarity
between the coefficients obtained for the U251 and
DU145 hybridizations suggests that storage of samples in
RNAlater reagent does not influence the results obtained
from microarray hybridization. The similarity between
the individual cores and their corresponding excisional
biopsy samples for both DU145 and U251 was then
assessed according to Pearson Coefficients (Table 1). For
each tumor the individual cores had correlations that
ranged from 0.75 to 0.85 when compared to the whole
tumor specimen for all genes and 0.95–0.97 for the out-
liers. Therefore, in these in vivo model systems the gene
expression profile generated from needle core biopsies
correlated to the gene expression profile of the whole
tumor.
Discussion
As microarray technology enters mainstream usage in
clinical oncology for class discovery and class prediction,
a major confounder in the generation of gene expression
profiles is likely to be the necessity of using small tissue
samples (<1 µg). To address this issue, we investigated
xenograft tumors to evaluate the similarity between
amplified and non-amplified specimens, the minimal
amount of starting material for RNA amplification that
retains fidelity, and the method of fluorophore probe
labeling. To our knowledge, this is the only study reported
to date evaluating all three of these variables in one
xenograft experiment. We then simulated a patient needle
core biopsy to determine whether the gene expression
profile generated from such a biopsy is representative of
the tumor.
A number of publications on the fidelity of amplified
RNA compared to total RNA generally conclude that the
amplified RNA does represent the total RNA sample par-
ticularly when comparing the outlier gene pattern [18-25]
As noted by Nygaard et al., however, gene expression
ratios are not always fully preserved [18]. In these publi-
cations, various starting material amounts, methods of
analysis, and methods of amplification varied greatly.
Feldman et al. recently demonstrated the advantages of
mRNA amplification for microarray analysis, however, in
their study cultured murine tumor cell lines were used
[16]. The data presented here is consistent with those
obtained from in vitro murine cell lines in that it illustrates
that total RNA from human xenografts can be purified,
amplified and hybridized using commercially available
kits to result in similar gene expression profiles for ampli-
fied RNA versus total RNA [16].
After validating that amplified RNA and total RNA prepa-
rations yielded similar results for all genes as well as the
outliers, we determined the amount of starting material
needed to begin the amplification process and retain
fidelity. Nygaard et al. recently published that 0.2 µg of
total RNA amplified 2 rounds yields an average correla-
tion between amplified and non-amplified arrays ranging
from 0.71 to 0.84 [18]. Similarly, Wang started with total
RNA in the 0.25–3.0 µg range and demonstrated no affect
on the fidelity or reproducibility of amplification
compared to the total RNA samples [26]. In each of these
Table 1: Pearson Coefficients between cores and corresponding tumor samples
Sample DU145 (LN2) Whole 
Tumor All Genes
DU145 (LN2) Whole 
Tumor Outliers
U251 (later) Whole 
Tumor All Genes
U251 (later) Whole 
Tumor Outliers
Core 1 0.827 0.979 0.824 0.950
Average N = 6,785 genes N = 436 genes N = 6,880 genes N = 381 genes
Core 2 0.846 0.979 0.750 0.972
Average N = 6,883 genes N = 416 genes N = 6,786 genes N = 396 genes
Core 3 0.812 0.970 0.834 0.973
Average N = 6,772 genes N = 340 genes N = 6,840 genes N = 389 genes
"All Genes" were extracted with the following parameters: Spots flagged as Bad/Not Found were excluded, and spots with target diameters outside 
of 50 µm and 300 µm were excluded. "Outliers" were extracted with the following parameters: Sgl/Bkg ratio >= 2, signal >= 1,000, override if 
either channel >= 2,500, target pixels 1 SD about Bkg >= 80%, target diameter btw 50 µm and 300 µm, genes required values in 100% of arrays, and 
ratio >= 2 in >= 2 arrays (applied symmetrically)BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/20
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studies the starting material was from cell culture. The
results presented here using starting material from human
xenograft models agrees with their findings: 0.5 µg of total
RNA amplified 2 rounds has a Pearson Coefficient of 0.7
when comparing the amplified RNA and total RNA speci-
mens. Because the amount of material generally obtained
from needle core biopsies is typically between 0.3 and 5
µg these results suggest that the amount of amplified RNA
generated from patient core biopsies can provide suffi-
cient material for microarray analysis. However, these
data also suggest that as the amount of total RNA starting
material decreases the coefficient of similarity to the
original specimen also decreases, which may contribute to
inconsistencies in data interpretation.
The two common labeling methods for microarray analy-
sis are direct and indirect (amino-allyl) labeling [27].
Direct labeling, which directly incorporates labeled nucle-
otides into cDNA during reverse transcription, is biased
towards the incorporation of Cy3 dye. This may be due to
either the inability of the reverse transcriptase (RT)
enzyme to efficiently incorporate bulky Cy-labeled dUTP
or the Cy labeled dye may be insoluble under RT condi-
tions. Indirect labeling overcomes this bias by incorporat-
ing the less-bulky amino-allyl modified nucleotides into
cDNA followed by the coupling of Cy3 and Cy5 to the
amino-allyl groups. Previous comparisons of the direct
and indirect labeling methods have shown similar
hybridization results, however, they have used total RNA
derived from cell culture or large amounts of normal tis-
sue starting material [28-30]. We have expanded upon
this data by verifying in a human xenograft model that the
results of hybridization comparisons between the direct
and indirect labeling methods produced similar results
and can therefore be directly compared. As the indirect
method uses less amplified starting material to produce a
probe, more hybridizations can be performed than with
the direct labeling method.
Having established that amplified RNA labeled indirectly
from a human xenograft model could be used for micro-
array analysis, it was then necessary to establish that core
biopsies would generate representative expression array
profiles compared to excisional biopsy material. Sotiriou
et al. using human tumor xenografts obtained a coeffi-
cient of 0.87 between two cores from the same tumor
using amplified RNA and coefficients of 0.77 and 0.78
between excisional biopsy total RNA and resultant core
biopsy amplified RNA [31]. Assersohn et al., also using a
human xenograft model, found a correlation of 0.76
between cores and 0.69 between cores and whole tumor
extracts [13]. Our findings for the coefficients between
cores and the whole tumor were in agreement with these
studies (range 0.75–0.85).
As the most common method of biopsy storage is to flash
freeze the specimen in liquid nitrogen, the majority of our
specimens were prepared in this manner. However, the
use of liquid nitrogen can be cumbersome to use in the
operating room. Recently, the reagent RNAlater has been
used to preserve RNA specimens at room temperature for
up to 24 hours. To evaluate this storage reagent, U251
tumors were biopsied and stored in both liquid nitrogen
and RNAlater. Consistent with prior studies, similar coef-
ficients were derived using either method of storage. Thus
it appears that snap freezing with liquid nitrogen or the
more convenient use of RNAlater is equivalent.
Conclusions
The data presented in this paper demonstrate that very
small amounts of human xenograft tissue (as low as 0.5
µg) can be amplified generating results that faithfully rep-
resent the corresponding total RNA samples. Fifty-five
percent of total RNA outliers were detected with this
amount of starting material. Because typical core biopsies
yield between 0.3–5 µg of starting material, they should
provide sufficient product for microarray experiments
after amplification has occurred. We have also demon-
strated that human xenograft core biopsies ranging from
0.5–5  µg of starting total RNA material yield Pearson
Coefficients between 0.750–0.846 when the amplified
core material is compared to the whole tumor. Taken
together, these experiments demonstrate that core biop-
sies after linear amplification and either indirect or direct
labeling can reliably be used for clinical oncology micro-
array studies.
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